The Effect of Somatostatin Analogue SMS 201—995 on Serotonin Levels in the Medium of Primary Carcinoid Cell Cultures

References

• Brazeau P., Vale W., Burgus R., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–9
   PubMed Web of Science ®Google Scholar
• Bauer W., Briner U., Doepfner W., et al. SMS 201–995, a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMed Web of Science ®Google Scholar
• Gorden P., (moderator). Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35–50
   PubMed Web of Science ®Google Scholar
• Tanner J. W., Davies S. K., McArthur N. H., French J. T., Welsh T. H. Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophyseal cells. J Endocrinol 1990; 125: 109–15
   PubMed Web of Science ®Google Scholar
• Redding T. W., Schally A. V. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci 1983; 80: 1078–82
   PubMed Web of Science ®Google Scholar
• Reubi J. C. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985; 109: 108–14
   PubMedGoogle Scholar
• Redding T. W., Schally A. W. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci 1984; 81: 248–52
   PubMed Web of Science ®Google Scholar
• Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J. K., Hahn R. G. Treatment of the malignant carcinoid syndrome. N Engl J Med 1966; 315: 663–6
   Google Scholar
• Lamberts S. W J, Krenning E. P. The effect of Sandostatin on hormone release by endocrne pancreatic tumors and their localization with a radioionated somatostatin analog ‘abstract S-3’. Biomed Res 1988; 9(Suppl 1)82
   Google Scholar
• Lamberts S. W J, Bakker W. H., Reubi J. V C, Krenning E. P. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. Metabolism 1990; 39(Suppl 2)152–5
   PubMedGoogle Scholar
• Coupe M., Levi S., Ellis M., et al. Therapy for symptoms in the carcinoid syndrome. Q J Med 1989; 73: 1021–36
   PubMedGoogle Scholar
• Ahlman H., Ahlund L., Dahlstrøm A., et al. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. Br J Cancer 1987; 56: 840–2
   PubMed Web of Science ®Google Scholar
• Öberg K., Norheim I., Theodorsson E., Ahlman H., Lundquist G., Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989; 68: 796–800
   PubMed Web of Science ®Google Scholar
• Vinik A., Moattari A. R. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34: 14–27
   PubMed Web of Science ®Google Scholar
• Norheim I., Theodorsson-Norheim E., Brodin E., Öberg K. Tachykinins in carcininoid tumours: Their use as a tumor marker and possible role in carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605–12
   PubMed Web of Science ®Google Scholar
• Jaffe B. Prostaglandins and serotonin: nonpeptide diarrheogenic hormones. World J Surg 1979; 3: 565–78
   PubMedGoogle Scholar
• Beubler E., Kollar G., Saria A., Bukhave K., Rask-Madsen J. Involvement of 5-hydroxytryptamine, prostaglandine E2 and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology 1989; 96: 368–76
   PubMed Web of Science ®Google Scholar
• Spatz M. Pathogenetic studies of experimentally induced heart lesions and their relation to the carcinoid syndrome. Lab Invest 1964; 13: 288–300
   PubMed Web of Science ®Google Scholar
• Debons-Guillemin M. C., Launay J. M., Roseto A., Peries J. Serotonin and histamine production by human carcinoid cells in culture. Cancer Res 1982; 42: 1513–6
   PubMed Web of Science ®Google Scholar
• Lawrence J. P., Ishizuka J., Haber B., Townsend C. M., Thompson J. C. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery 1990; 108: 1131–5
   PubMed Web of Science ®Google Scholar
• Sasa S., Blank C. L., Wenke D. C., Sczupak C. A. Liquid-chromatographic determination of serotonin in serum and plasma. Clin Chem 1978; 24: 1509–14
   PubMed Web of Science ®Google Scholar
• Harris A. Future medical prospects for Sandostatin. Metabolism 1990; 39(Suppl 2)180–5
   PubMedGoogle Scholar
• Patel Y. C., Murthy K. K., Escher E. E., Banville D., Spiess J., Srikant C. B. Mechanism of action of somatostatin: An overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39(Suppl 2)63–9
   PubMedGoogle Scholar
• Barasch J., Mackey H., Tamir H., Nunez E. A., Gershon M. D. Induction of a neural phenotype in a serotonergic endocrine cell derived from the neural crest. Neuroscience 1987; 7: 2874–83
   PubMed Web of Science ®Google Scholar
• Lendahl U., McKay R. D G. The use of cell lines in neurobiology. Trends Neurosci 1990; 13: 132–7
   PubMed Web of Science ®Google Scholar
• Ahlman H., Åhlund L., Nilsson O., Skolnik G., Theodorsson E., Dahlstrøm A. Carcinoid tumour cells in long-term culture: Release of serotonin but not of tachykinins on stimulation with adrenoreceptor agonists. Int J Cancer 1988; 42: 506–10
   PubMed Web of Science ®Google Scholar
• Ahlman H., Wigander A., Mølne J., et al. Presence of nerve growth factor-like immunoreactivity in carcinoid tumour cells and induction of a neuronal phenotype in long-term culture. Int J Cancer 1989; 43: 945–55
   Web of Science ®Google Scholar
• Funa K., Papanicolaou V., Juhlin C., et al. Expression of platelet-derived growth-factor beta-receptors on stromal tissue cells in human carcinoid tumours. Cancer Res 1990; 50: 748–53
   PubMed Web of Science ®Google Scholar
• Pelletier G., Cortot A., Launay J. M., et al. Serotonin-secreting and insulin-secreting ileal carcinoid tumor and the use of in vitro culture of tumoral cells. Cancer 1984; 54: 319–24
   PubMed Web of Science ®Google Scholar
• Richardson U. I., Schonbrunn A. Inhibition of adrenocortico-tropin secretion by somatostatin in pituitary cells in culture. Endocrinology 1981; 108: 281–90
   PubMed Web of Science ®Google Scholar
• Bjøro T., Østberg B., Sand O., et al. Somatostatin inhibits prolactin secretion by multiple mechanisms involving a site of action distal to increased cyclic adenosine-3′,5′-monophosphate and elevated cytosolic Ca++ in rat lactotrophs. Acta Physiol Scand 1988; 133: 271–82
   PubMedGoogle Scholar
• Kraicer J., Spence S. W. Release of growth hormone from purified somatotrophs: use of high K+ inophore A 23187 to elucidate interelations among Ca++, adenosin-3′,5′-monophosphate, and somatostatin. Endocrinology 1981; 108: 651–7
   PubMed Web of Science ®Google Scholar
• Schlegel W., Wuarin F., Wollheim C. B., Zahnd G. R. Somatostatin lowers the cytosolic free Ca++ concentration in clonal rat pituitary (GH4 cells). Cell Calcium 1984; 5: 223–36
   PubMed Web of Science ®Google Scholar
• Schlegel W., Winiger B. P., Mollard P., et al. Oscillations of cytosolic Ca++ in pituitary cells due to action potentials. Nature 1987; 329: 719–21
   PubMed Web of Science ®Google Scholar
• Stachura M. E. Potassium modification of the somatostatin effect on stimulated rat growth hormone release. Endocrinology 1981; 108: 1027–34
   PubMed Web of Science ®Google Scholar
• Østberg B. C., Sand O., Bjøro T., Haug E. The phorbol esther TPA induces hormone release and electric activity in clonal rat pituitary cells. Acta Physiol Scand 1986; 126: 517–24
   PubMedGoogle Scholar
• Srkalovic G., Cai R. Z., Schally A. V. Evaluation of receptors for somatostatin in various tumours using different analogs. J Clin Endocrinol Metab 1990; 70: 661–9
   PubMed Web of Science ®Google Scholar